Eli Lilly is one of the world’s leading pharmaceutical companies.
Eli Lilly delivered the most extraordinary single-year financial performance in pharmaceutical history in 2025 — full year revenues of $65.2 billion, a 45% increase from 2024, driven by Mounjaro and Zepbound. The company has guided to revenues of $80-83 billion for 2026. Kisunla’s approval as the first anti-amyloid antibody from Lilly for Alzheimer’s disease opens a second potential blockbuster franchise. Lilly’s manufacturing investment — $50 billion committed to new capacity expansion — reflects the company’s confidence in sustained demand growth.
This report provides comprehensive strategic intelligence on Eli Lilly — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Eli Lilly — Key Financial Metrics 2023-2025
Table 2. Eli Lilly — Revenue by Therapeutic Area 2023-2025
Table 3. Eli Lilly — Revenue by Geography 2023-2025
Table 4. Eli Lilly — R&D Investment 2023-2025
Table 5. Eli Lilly — SWOT Analysis
Table 6. Eli Lilly — Key Technology Platforms
Table 7. Eli Lilly — Top Products by Revenue 2025
Table 8. Eli Lilly — Late-Stage Pipeline 2025
Table 9. Eli Lilly — M&A Activity 2023-2025
Table 10. Eli Lilly — Key Management
Table 11. Eli Lilly — Strategic Priorities 2025-2030
